Rockefeller Capital Management L.P. Summit Therapeutics Inc. Transaction History
Rockefeller Capital Management L.P.
- $47.9 Billion
- Q3 2025
A detailed history of Rockefeller Capital Management L.P. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Rockefeller Capital Management L.P. holds 33 shares of SMMT stock, worth $601. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33Holding current value
$601% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
263Shares Held
93.5MCall Options Held
4.72MPut Options Held
4.03M-
Baker Bros. Advisors LP New York, NY33.7MShares$615 Million5.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$208 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
State Street Corp Boston, MA6.36MShares$116 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.54MShares$82.8 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.67B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...